A prospective natural history study of inclusion body myositis: implications for clinical trials.
Eleven patients with untreated inclusion body myositis (IBM) were prospectively studied during a 6-month period that included muscle strength, lean body mass, and muscle mass measurements. There was an overall quantifiable mean decline in percent of predicted normal muscle strength of 4% from baseline in a 6-month period, but one third of patients showed no change or slight improvements in strength. Short-term treatment trials in IBM will require large numbers of patients to detect slowing, arrest, or even slight improvement in muscle strength.
Rose
M R
MR
Department of Neurology, King's Neurosciences Centre, King's College Hospital, London, UK. m.r.rose@kcl.ac.uk
McDermott
M P
MP
Thornton
C A
CA
Palenski
C
C
Martens
W B
WB
Griggs
R C
RC
D000368:Aged; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018979:Myositis, Inclusion Body / Q000503:physiopathology*